Korea’s KRICT reported a novel viral vector technology aimed at improving CAR immune cell production. The approach centers on a newly identified SRV2 envelope protein to enhance CAR immune cell manufacturing, with the work led by Dr. Chi Hoon Park at the Korea Research Institute of Chemical Technology. The development targets a key constraint for CAR therapies—scale and consistency of vector-driven manufacturing—by modifying the viral-vector input to improve output during production workflows. If validated at scale, the platform could reduce bottlenecks in CAR T-cell generation and support wider accessibility. For sponsors, vector performance improvements can directly impact lead times, batch success rates, and ultimately the feasibility of larger clinical and commercialization programs.